Type 2 Diabetes, but Not Insulin (Analog) Treatment, Is Associated With More Advanced Stages of Breast Cancer: A National Linkage of Cancer and Pharmacy Registries.

Autor: Overbeek JA; Department of General Practice and Elderly Care Medicine, Amsterdam Public Health Research Institute, VU University Medical Center, Amsterdam, the Netherlands jetty.overbeek@pharmo.nl.; PHARMO Institute for Drug Outcomes Research, Utrecht, the Netherlands., van Herk-Sukel MPP; Department of Internal Medicine and Dermatology, University Medical Center Utrecht, Utrecht, the Netherlands., Vissers PAJ; Department of Research, Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands., van der Heijden AAWA; Department of General Practice and Elderly Care Medicine, Amsterdam Public Health Research Institute, VU University Medical Center, Amsterdam, the Netherlands., Bronsveld HK; Department of Acute Care and Oncology, Nestlé Health Science, Lausanne, Switzerland., Herings RMC; PHARMO Institute for Drug Outcomes Research, Utrecht, the Netherlands.; Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands., Schmidt MK; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Nijpels G; Department of General Practice and Elderly Care Medicine, Amsterdam Public Health Research Institute, VU University Medical Center, Amsterdam, the Netherlands.

Publikováno v: Diabetes care [Diabetes Care] 2019 Mar; Vol. 42 (3), pp. 434-442. Date of Electronic Publication: 2019 Jan 24.

Trends in breast cancer incidence among women with type-2 diabetes in British general practice.

Autor: Bronsveld HK; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands; Division Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: H.Bronsveld@nki.nl., Peeters PJHL; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. Electronic address: P.J.H.L.Peeters@uu.nl., de Groot MCH; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands; Department of Clinical Chemistry and Haematology, Division of Laboratory and Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands. Electronic address: M.C.H.deGroot-3@umcutrecht.nl., de Boer A; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. Electronic address: A.deBoer@uu.nl., Schmidt MK; Division Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: mk.schmidt@nki.nl., De Bruin ML; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands; Copenhagen Centre for Regulatory Science, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Electronic address: M.L.DeBruin@uu.nl.

Publikováno v: Primary care diabetes [Prim Care Diabetes] 2017 Aug; Vol. 11 (4), pp. 373-382. Date of Electronic Publication: 2017 Feb 23.

Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence.

Autor: Bronsveld HK; Division of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. h.bronsveld@nki.nl.; Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands. h.bronsveld@nki.nl., ter Braak B; Division of Toxicology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands. basterbraak@gmail.com., Karlstad Ø; Department of Pharmacoepidemiology, Norwegian Institute of Public Health, Oslo, Norway. Oystein.Karlstad@fhi.no., Vestergaard P; Departments of Clinical Medicine and Endocrinology, Aalborg University, Aalborg, Denmark. p-vest@post4.tele.dk., Starup-Linde J; Departments of Clinical Medicine and Endocrinology, Aalborg University, Aalborg, Denmark. Jakob.Linde@auh.rm.dk.; Department of Endocrinology and Internal Medicine (MEA), Aarhus University Hospital THG, Aarhus, Denmark. Jakob.Linde@auh.rm.dk., Bazelier MT; Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands. M.T.Bazelier@uu.nl., De Bruin ML; Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands. M.L.deBruin@uu.nl., de Boer A; Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands. a.deboer@uu.nl., Siezen CL; Medicines Evaluation Board (MEB), Utrecht, The Netherlands. cl.siezen@cbg-meb.nl., van de Water B; Division of Toxicology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands. water_b@lacdr.leidenuniv.nl., van der Laan JW; Division of Toxicology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands. jw.vd.laan@cbg-meb.nl.; Medicines Evaluation Board (MEB), Utrecht, The Netherlands. jw.vd.laan@cbg-meb.nl.; Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands. jw.vd.laan@cbg-meb.nl., Schmidt MK; Division of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. mk.schmidt@nki.nl.

Publikováno v: Breast cancer research : BCR [Breast Cancer Res] 2015 Aug 05; Vol. 17, pp. 100. Date of Electronic Publication: 2015 Aug 05.